Clin2
NCT07296328Possibly a fitNot yet recruiting

Psilocybin for stuttering: speech fluency and brain activity study

Stuttering

Treatments studied

Part of Brain & nervous system clinical trials.

This trial tests a single dose of psilocybin, a psychedelic compound, to see if it can improve speech fluency and reduce struggle in adults who stutter. It also looks at changes in brain activity using fMRI scans. The study involves preparation sessions, a psilocybin session, and follow-up visits.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
25 people
Ages
18 years to 50 years
Study type
Interventional

Who can take part

  • You must be 18 to 50 years old.
  • You must have a diagnosis of mild-moderate to severe stuttering, confirmed by a specialist.
  • You must be able to read, speak, and understand English.
  • You must agree to stop taking any non-prescribed drugs or supplements for a period before and after the study.
  • You must be willing to use effective birth control if you could become pregnant or get someone pregnant.
  • You cannot have certain medical or psychiatric conditions, including heart disease, seizure disorder, severe mental illness, or recent use of psychedelics.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07222163Recruiting
Stuttering study with brain stimulation

This study tests whether a safe, non-invasive brain stimulation technique called tDCS can help reduce stuttering. It involves attending several sessions where you receive either active stimulation or a placebo, while you speak or do tasks.

New York, New York
NCT07449351Not yet recruiting· Early Phase 1
Psilocybin microdosing study for cognition and mood

This study tests whether very small, repeated doses of psilocybin (a substance found in certain mushrooms) can improve thinking, mood, and quality of life. It is for adults who have never used psychedelics and are in good general health, both mentally and physically.

Hartford, Connecticut
NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut
NCT06349083Recruiting· Phase 2
Psilocybin-assisted treatment for alcohol use disorder

This study tests whether psilocybin, a psychedelic drug, combined with therapy can help people reduce or stop drinking. It aims to understand how psilocybin affects the brain and behavior in people with alcohol use disorder.

New York, New York
NCT07079852Not yet recruiting· Phase 1/Phase 2
Psilocybin and its effects on memory and brain function

This trial tests how psilocybin, a psychedelic substance, affects your thinking, memory, and brain activity. Researchers want to understand these effects in healthy adults who have used psychedelics before.

Austin, Texas
NCT07053917Recruiting· Phase 1
Psilocybin therapy for stroke recovery

This trial tests whether a medicine called psilocybin (a psychedelic compound) can help people who had a stroke more than a year ago. It aims to see if the therapy can improve healing and flexibility in the brain.

Baltimore, Maryland

Hear when a new Stuttering trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.